Chronopharmacology of oxacalcitriol in rat model of osteoporosis

European Journal of Pharmacology

Volumn 488, Issue 1-3, 2004, Pages 239-245

  Tsuruoka, Shuichi ^a   Wakaumi, Michis ^a   Yamamoto, Hisashi ^a   Fujimura, Akio ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

22 Oxacalcitriol; Chronotherapy; Hypercalcemia; Osteoporosis

Indexed keywords

22 OXACALCITRIOL; ALBUMIN; BINDING PROTEIN; CALCIUM; CREATININE; DEOXYPYRIDINOLINE; PARATHYROID HORMONE; VITAMIN D DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT DISORDER; BONE DENSITY; CALCIUM BLOOD LEVEL; CHRONOPHARMACOLOGY; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; FEMUR; HYPERCALCEMIA; HYPERPHOSPHATEMIA; LIGHT; LIGHT DARK CYCLE; MALE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RAT; URINARY EXCRETION;

AMINO ACIDS; ANIMALS; BODY WEIGHT; BONE DENSITY; CALCITRIOL; CALCIUM; CREATININE; DENSITOMETRY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; OSTEOPOROSIS; PARATHYROID HORMONE; PHOSPHORUS; RATS; RATS, INBRED SHR; SERUM ALBUMIN; TIME FACTORS;

EID: 1642283430     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.02.007     Document Type: Article

References (30)

1. Brown A.J., Finch J., Grieff M., Ritter C., Kubodera N., Nishii Y., Slatopolsky E. The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology. 133:1993;1158-1164.
2. Calvo M.S., Eastell R., Offord K.P., Bergstralh E.J., Burritt M.F. Circadian variation in ionized calcium and intact parathyroid hormone: evidence for sex differences in calcium homeostasis. J. Clin. Endocrinol. Metab. 72:1991;69-76.
3. Connerty H., Briggs A. Determination of serum calcium by means of orthocresolphtalein complexone. Am. J. Clin. Pathol. 45:1966;290-296.
4. Drewes P. Direct colorimetric determination of phosphorus in serum and urine. Clin. Chim. Acta. 39:1972;81-88.
5. Farach-Carson M.C., Abe J., Nishii Y., Khoury R., Wright G.C., Norman A.W. 22-Oxacalcitriol: dissection of 1,25(OH)2D3 receptor-mediated and Ca2+ entry-stimulating pathways. Am. J. Physiol. 265:1993;F705-F711.
6. Fukuda S., Tsuchikura S., Iida H., Ikeda K., Nara Y., Yamori Y. Further study on osteoporosis in SHRSP: quantitative analysis by bone histomorphometry and serum biochemical constituents related to bone. Genet. Hypertens. 218:1992;421-423.
7. Fukuda S., Tsuchikura S., Iida H., Ikeda K., Nara Y., Yamori Y. Intestinal calcium absorption and response of calcium regulating hormones in the stroke-prone spontaneously hypertensive rat as a model of osteoporosis. Clin. Exp. Pharmacol. Physiol. 22(Suppl 1):1995;S240-S241.
8. Ishigai M., Asoh Y., Kumaki K. Determination of 22-oxacalcitriol, a new analog of 1 alpha, 25-dihydroxy vitamin D3, in human serum by liquid chromatography-mass spectrometry. J. Chromatogr., B, Biomed. Sci. Appl. 706:1998;261-267.
9. Kobayashi T., Tsugawa N., Okano T., Masuda S., Takeuchi A., Kubodera N., Nishii Y. The binding properties, with blood proteins, and tissue distribution of 22-oxa-1 alpha, 25-dihydroxy vitamin D3, a noncalcemic analogue of 1 alpha, 25-dihydroxy vitamin D3, in rats. J. Biochem. (Tokyo). 115:1994;373-380.
10. Kubrusly M., Gagne E.R., Urena P., Hanrotel C., Chabanis S., Lacour B., Drueke T.B. Effect of 22-oxa-calcitriol on calcium metabolism in rats with severe secondary hyperparathyroidism. Kidney Int. 44:1993;551-556.
11. Mrosovsky N., Salmon P. A behavioural method for accelerating re-entrainment of rhythms to new dark-light cycles. Nature (Lond.). 330:1987;372-373.
12. Nishiki K., Tsuruoka S., Wakaumi M., Yamamoto H., Koyama A., Fujimura A. Dosing time-dependent variation in the hypocalcemic effect of calcitonin in rat. Eur. J. Pharmacol. 460:2003;171-175.
13. Parfitt A.M. Use of calciferol and its metabolites and analogues in osteoporosis. Current status. Drugs. 36:1988;513-520.
14. Seyedin S., Kung V., Danilhoff Y., Hesley R., Gomez B., Nielsen L., Rosen H., Zuk R. Immunoassay for urinary pyridinoline: the new marker of bone resorption. J. Bone Miner. Metab. 8:1993;635-642.
15. Shen V., Birchman R., Xu R., Lindsay R., Dempster D.W. Short-term changes in histomorphometric and biochemical turnover markers and bone mineral density in estrogen- and/or dietary calcium-deficient rats. Bone. 16:1995;149-156.
16. Shinoda H., Seto H. Diurnal rhythms in calcium and phosphate metabolism in rodents and their relations to lighting and feeding schedules. Miner. Electrolyte Metab. 11:1985;158-166.
17. Shinoda H., Stern P.H. Diurnal rhythms in Ca transfer into bone, Ca release from bone, and bone resorbing activity in serum of rats. Am. J. Physiol. 262:1992;R235-R240.
18. Sugimoto K., Tobian L., Ishimitsu T., Lange J.M. High potassium diets greatly increase growth-inhibiting agents in aortas of hypertensive rats. Hypertension. 19:1992;749-752.
19. Sugimoto K., Tsuruoka S., Fujimura A. Renal protective effect of YM598, a selective endothelin ET(A) receptor antagonist, against diabetic nephropathy in OLETF rats. Eur. J. Pharmacol. 450:2002;183.
20. Takahashi J., Zatz M. Regulation of circadian rhythmicity. Science (Wash.). 217:1982;1104-1111.
21. Takamure M., Murakami N., Takahashi K., Kuroda H., Etoh T. Rapid re-entrainment of the circadian clock itself, but not the measurable activity rhythms to a new light-dark cycles in the rat. Physiol. Behav. 50:1991;443-449.
22. Tobian L. High-potassium diets markedly protect against stroke deaths and kidney disease in hypertensive rats, an echo from prehistoric days. J. Hypertens. (Suppl 4):1986;S67-S76.
23. Tsuruoka S., Sugimoto K., Ohmori M., Kawaguchi A., Saito T., Fujimura A. Chronotherapy of high-dose 1,25-dihydroxy vitamin D3 in hemodialysis patients with secondary hyperparathyroidism: a single-dose study. Clin. Pharmacol. Ther. 66:1999;609-616.
24. Tsuruoka S., Sugimoto K., Fujimura A. Contribution of the diet to the dosing time-dependent change of vitamin D3 induced hypercalcemia in rats. Life Sci. 68:2000;579-589.
25. Tsuruoka S., Nishiki K., Sugimoto K., Fujimura A. Chronotherapy with active vitamin D3 in aged stroke-prone spontaneously hypertensive rats, a model of osteoporosis. Eur. J. Pharmacol. 428:2001;287-293.
26. Tsuruoka S., Nishiki K., Sugimoto K., Fujimura A. Time of day improves efficacy and reduces adverse reactions of vitamin D3 in 5/6 nephrectomized rat. Life Sci. 71:2002;1809-1820.
27. Tsuruoka S., Wakaumi M., Sugimoto K., Saito T., Fujimura A. Chronotherapy of high-dose active vitamin D3 in haemodialysis patients with secondary hyperparathyroidsm: a repeated dosing study. Br. J. Clin. Pharmacol. 55:2003;531-537.
28. Turek F. Circadian neural rhythms in mammals. Annu. Rev. Physiol. 47:1985;49-64.
29. Yamauchi H., Kobayashi E., Sugimoto K., Tsuruoka S., Yabana M., Ishii M., Fujimura A. Time-dependent cyclosporine A-induced nephrotoxicity in rats. Clin. Exp. Pharmacol. Physiol. 25:1998;435-440.
30. Yamori Y., Fukuda S., Tsuchikura S., Ikeda K., Nara Y., Horie R. Stroke-prone SHR (SHRSP) as a model for osteoporosis. Clin. Exp. Hypertens., Part A Theory Pract. 13:1991;755-762.